Clinical trials: Cardiogenic Shock, active
Medical Condition Requiring Extracorporeal Organ Support
The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry
A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of…
- Trial name
- NCT05811780
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital Freiburg
Cardiogenic Shock
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
International, observational registry to investigate the outcome in patients with cardiogenic shock. The primary aim of this study is to investigate the clinical outcome of patients in cardiogenic shock.
- Trial name
- STOP-SHOCK (NCT03313687)
- Where
- Germany
- Volunteers
- 2,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cardiogenic Shock
Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock
The registry objective is to get information on current epidemiology, diagnostics, treatment and outcome in patients with cardiogenic shock in Poland.
- Trial name
- CaS-POL (NCT06697093)
- Where
- 2 sites in Poland
- Volunteers
- 500 people
- Sponsor
- Wroclaw Medical University
Sudden Cardiac Arrest, Out-of-hospital Cardiac Arrest (OHCA)
FEMART-1 Pilot Study
The FEMART-1 Pilot Study is focused on evaluating the feasibility, safety, and procedural timing of prehospital femoral arterial sheath placement in patients with non-traumatic out-of-hospital cardiac arrest (OHCA), both during…
- Conditions
- Sudden Cardiac Arrest, Out-of-hospital Cardiac Arrest (OHCA), Cardiogenic Shock Acute
- Trial name
- FEMART-1 (NCT07596446)
- Testing
- Prehospital Ultrasound-Guided Femoral Arterial Sheath Placement
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Emergency Medical Service, Prague
ECMO Treatment, ARDS (Acute Respiratory Distress Syndrome)
Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients
This study evaluates the safety and effectiveness of Ciprofol, a new sedative, in critically ill patients receiving Extracorporeal Membrane Oxygenation (ECMO), a life-support system for heart or lung failure.
- Conditions
- ECMO Treatment, ARDS (Acute Respiratory Distress Syndrome), ECMO and Acute MI, Respiratory Failure Patients Treated With ECMO
- Trial name
- CIP-OXY (NCT06934811)
- Testing
- Ciprofol, Midazolam
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Cardiogenic Shock
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
The goal of this clinical trial is to learn if the drug istaroxime works to treat cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime.
- Trial name
- RESCUE HF-CS (NCT07583446)
- Testing
- istaroxime
- Where
- Armenia
- Volunteers
- 600 people
- Sponsor
- Seismic Pharmaceuticals Operations LLC
Acute Myocardial Infarction, Cardiogenic Shock
Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
In the present study, we aim to investigate the effects of dobutamine infusion and/or a single intravenous (IV) dose of the IL-6 antagonist Tocilizumab administered after percutaneous coronary intervention (PCI) to patients with…
- Trial name
- DOBERMANN (NCT05350592)
- Testing
- Tocilizumab, Dobutamine, NaCl 0.9%
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cardiogenic Shock, Mechanical Circulatory Support
OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science
The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and…
- Conditions
- Cardiogenic Shock, Mechanical Circulatory Support, Cardiogenic Shock Post Myocardial Infarction
- Trial name
- OPTIMIZE (NCT07619144)
- Testing
- Micro-axial flow pump support
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Medical University of Vienna
Respiration Failure, Cardio Vascular Disease
COMPARE-VENT Feasibility Pilot Study
Cardiac disease complicated by respiratory insufficiency comprises the most frequent indication for cardiac intensive care unit (CICU) admission, with nearly one-third patients requiring advanced respiratory support and over 20%…
- Conditions
- Respiration Failure, Cardio Vascular Disease, Cardiogenic Pulmonary Oedema, Critical Illness
- Trial name
- NCT07656259
- Testing
- Volume Controlled Mode, Pressure Controlled Mode
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Intensive Care Medicine, Respiratory Distress Syndrome (RDS)
Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol
Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable.
- Conditions
- Intensive Care Medicine, Respiratory Distress Syndrome (RDS), Sedation and Analgesia, ExtraCorporeal Membrane Oxygenation (ECMO)
- Trial name
- ECMO-SED (NCT07032987)
- Testing
- Not an intervention study
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
Cardiogenic Shock, Acute Myocardial Infarction
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and…
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
- Trial name
- NCT07825363
- Testing
- NIRSense Tissue Oximetry Sensor System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NIRSense Inc.
Heart Failure With Reduced Ejection Fraction, Cardiogenic Shock
Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection…
- Trial name
- PACE-SHOCK (NCT06078436)
- Testing
- Pulmonary artery catheter
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Min-Seok Kim
Cardiogenic Shock Acute, Bypass, Cardiopulmonary
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock
Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation.
- Conditions
- Cardiogenic Shock Acute, Bypass, Cardiopulmonary, Septic Shock, Mechanical Circulatory Support
- Trial name
- PROMIX (NCT07354568)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Heart Failure, Cardiogenic Shock
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1.
- Conditions
- Heart Failure, Cardiogenic Shock, Congenital Heart Disease, Cardiomyopathies
- Trial name
- TROLLEY (NCT06080074)
- Testing
- Cardiohelp device (VA-ECMO), Heparin, Bivalirudin
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction
Hong Kong Cardiogenic Shock Initiative
Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a severe condition with high mortality. Early revascularization and Impella device (Abiomed) support improve outcomes.
- Conditions
- Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction, Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction
- Trial name
- HK CSI (NCT07323238)
- Where
- Hong Kong
- Volunteers
- 320 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Cardiogenic Shock
Abiomed Impella RT-DAQ - Observational Study
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
- Trial name
- NCT06308055
- Testing
- Data Acquisition
- Where
- 4 sites in Germany, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- Abiomed Inc.
Cardiogenic Shock
French Observatory on the Management of Cardiogenic Shock 2
The aim of this observational study is to describe the baseline characteristics, management strategies, and early outcomes (during hospitalisation and at 30 days) of patients admitted to intensive care with cardiogenic shock…
- Trial name
- FRENSHOCK 2 (NCT07868757)
- Where
- 2 sites in France
- Volunteers
- 1,000 people
- Sponsor
- French Cardiology Society
Cardiogenic Shock
The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care
Cardiogenic shock is a frequent reason for hospitalization in critical care units, with high mortality (50%). Several French registries have been created to improve knowledge of the prognostic factors of cardiogenic shock.
- Trial name
- HEMOCARD (NCT05752383)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc